Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of “Moderate Buy” from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $8.20.

A number of research analysts have issued reports on the company. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday. HC Wainwright reduced their price target on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Tuesday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SANA. SG Americas Securities LLC increased its holdings in Sana Biotechnology by 32.4% during the 1st quarter. SG Americas Securities LLC now owns 130,083 shares of the company’s stock valued at $375,000 after purchasing an additional 31,796 shares in the last quarter. Hsbc Holdings PLC raised its position in Sana Biotechnology by 20.2% in the 4th quarter. Hsbc Holdings PLC now owns 94,064 shares of the company’s stock valued at $375,000 after purchasing an additional 15,836 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares in the last quarter. Virtu Financial LLC boosted its stake in Sana Biotechnology by 189.4% in the fourth quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock worth $486,000 after purchasing an additional 78,088 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Sana Biotechnology by 24.1% during the fourth quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock worth $2,287,000 after purchasing an additional 109,078 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $3.52 on Friday. The company has a market capitalization of $939.38 million, a PE ratio of -3.63 and a beta of 2.06. Sana Biotechnology has a one year low of $1.59 and a one year high of $6.55. The business has a 50 day simple moving average of $3.47 and a 200 day simple moving average of $4.12.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Equities analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.